Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update regarding its on-market share buyback program, appointing J.P. Morgan Securities Australia Limited as the broker for the transaction. This strategic move is part of CSL’s ongoing efforts to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its position in the market.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of products for the treatment of serious medical conditions, including blood plasma derivatives and vaccines. The company is a key player in the global healthcare market, providing essential therapies and services.
Average Trading Volume: 997,842
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.